Popular Biotech News, Healthcare News and Pharma News

12:05 EST 17th November 2017 | BioPortfolio

Fostair® (beclometasone and formoterol) 200/6 high strength formulation now available for asthma maintenance therapy at no additional cost

Manchester, 1 December 2015 – Chiesi Limited today announced that the high strength formulation of Fostair (beclometasone/formoterol) 200/6 is now available for the regular treatment of adult asthma where the use of an inhaled corticosteroid (ICS) and long-acting beta-2-agonist (LABA) combination product is appropriate and where treatment needs to be stepped up. The introduction of the new...

Protein Plus LLC to Exhibit at SOHO Expo, December 2 - 3

Attendees have the opportunity to sample products and receive a special trade show discount at booth #106 KISSIMMEE, FL--(Marketwired - Nov 13, 2017) - Read more...

Quick Search